The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2021 | MRD: its role and importance for myeloma treatment
Katja Weisel, MD, of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the role of measurable residual disease (MRD) in the treatment of myeloma and its importance for patients. Dr Weisel also explains that MRD assessment results should be considered with caution as this is not the only measurement and is not definitive of complete remission or relapse. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Katja Weisel, MD, has received institutional grant support from Amgen, BMS/Celgene, GSK and Sanofi; and has received honoraria from AbbVie, Amgen, Adaptive Biotech, BMS/Celgene, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche Pharma, Takeda and Sanofi.
